OncoMatch/Clinical Trials/NCT06657144
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Is NCT06657144 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including CHS-114 and Toripalimab for metastatic solid tumor.
Treatment: CHS-114 · Toripalimab · 5 Fluorouracil · Cisplatin — The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Tumor Agnostic
Biomarker criteria
Required: HER2 (ERBB2) negative
HER2-negative
Required: MMR proficient mismatch repair
microsatellite stable (MSS)/proficient mismatch repair (pMMR)
Required: MSI microsatellite stable
microsatellite stable (MSS)/proficient mismatch repair (pMMR)
Required: PD-L1 (CD274) expression (IHC assay score required; no threshold specified)
Consent to provide results from prior PD-L1 IHC assay score by FDA-approved or equivalent PD-L1 IHC diagnostic tests
Required: RAS status documented
RAS...status for each participant must be documented
Required: BRAF status documented
BRAF...status for each participant must be documented
Required: MSI status documented
microsatellite instability/mismatch repair status for each participant must be documented
Required: MMR status documented
microsatellite instability/mismatch repair status for each participant must be documented
Disease stage
Required: Stage III, IV
Metastatic disease required
unresectable, locally advanced or metastatic...at least 1 measurable lesion based on RECIST v1.1
Prior therapy
Must have received: platinum-based chemotherapy — first line
Progressed during or after first line systemic therapy that includes a platinum and fluoropyrimidine doublet
Must have received: fluoropyrimidine — first line
Progressed during or after first line systemic therapy that includes a platinum and fluoropyrimidine doublet
Must have received: platinum-based chemotherapy — first line
Progressed during or after first line systemic therapy including a doublet of platinum and fluoropyrimidine or paclitaxel
Must have received: taxane (paclitaxel) — first line
Progressed during or after first line systemic therapy including a doublet of platinum and fluoropyrimidine or paclitaxel
Cannot have received: systemic anticancer therapy
Received 2 prior systemic anticancer therapies for advanced or metastatic disease
Cannot have received: systemic anticancer therapy
Received 1 prior systemic anticancer therapies for advanced or metastatic disease
Cannot have received: anti-C-C motif chemokine receptor 8 (CCR8) antibody
Prior exposure to anti-C-C motif chemokine receptor 8 (CCR8) antibody
Lab requirements
Kidney function
Calculated creatinine clearance 60 mL/min
Calculated creatinine clearance 60 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Arizona Cancer Center · Tucson, Arizona
- City of Hope · Duarte, California
- University of Colorado - Aurora Cancer Center · Aurora, Colorado
- Winship Cancer Center - Emory University · Atlanta, Georgia
- Ochsner Health · New Orleans, Louisiana
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06657144 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anticancer therapy, systemic anticancer therapy, anti-C-C motif chemokine receptor 8 (CCR8) antibody disqualifies patients from enrollment.
Does this trial require ERBB2?
Yes, ERBB2 negative is a required biomarker for enrollment.
Does this trial require MMR?
Yes, MMR proficient mismatch repair is a required biomarker for enrollment.
Does this trial require MSI?
Yes, MSI microsatellite stable is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify